Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 2540 • 2018 ACR/ARHP Annual Meeting
Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Xavier Mariette¹, Elodie Perrodeau², Christian Verner³, Xavier Struillou⁴, Thierry Schaeverbeke⁵, Alain Cantagrel⁶, Philippe Ravaud⁷ and Philippe Bouchard⁸, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Paris Hotel Dieu, Paris, France, ³Periodontology, UFR d'odontologie, University of Nantes, Nantes, France, ⁴Periodontology, UFR d'odontologie, University of Nantes,, Nantes, France, ⁵Rheumatology, CHU Bordeaux, Bordeaux, France, ⁶Rheumatology, CHU Toulouse, Toulouse, France, ⁷INSERM UMR1153, Paris Descartes University, Paris, France, ⁸Paris Diderot University, Paris, France
Background/Purpose: Good evidence suggests a relationship between rheumatoid arthritis (RA) and periodontitis. We aimed to investigate if a good oral hygiene could improve activity of…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 2543 • 2018 ACR/ARHP Annual Meeting
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim¹, Eun-Young Lee², Sun Kyung Lee³, Yong-Beom Park⁴, Young Nam Lee⁵, HeeJung Kang⁶ and Kichul Shin⁷, ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Department of Medical Informatics, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Celltrion Healthcare Co. Ltd, Incheon, Korea, Republic of (South), ⁶Celltrion Healthcare Co.Ltd, Incheon, Korea, Republic of (South), ⁷Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: CT-P13 is a biosimilar prescribed in a number of countries for indications approved for the reference infliximab (RINF) including rheumatoid arthritis (RA), ankylosing spondylitis…
Abstract Number: 579 • 2018 ACR/ARHP Annual Meeting
Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
Cameron Adams¹, Katie Marker¹, Melissa Krueger², Lisa Barcellos¹ and Lindsey A. Criswell³, ¹School of Public Health, UC Berkeley, Berkeley, CA, ²UC San Francisco, San Francisco,, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Epigenetic modifications including DNA methylation are implicated in the development and progression of autoimmune diseases, such as rheumatoid arthritis [MIM 180300]. Evidence indicates that…
Abstract Number: 2549 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Vibeke Strand¹, Matthew Reaney², Erin Mangan³, Hubert van Hoogstraten⁴, Susan Boklage³ and Chih-Chi Hu⁵, ¹Stanford University School of Medicine, Palo Alto, CA, ²Sanofi, Guildford, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab is a human monoclonal antibody that binds to membrane and soluble IL-6R, which is approved for the treatment of moderate to severe rheumatoid…
Abstract Number: 587 • 2018 ACR/ARHP Annual Meeting
The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
Ruediger Mueller¹, Michael Spaeth², Cord von Restorff³, Christoph Ackermann⁴ and Johannes von Kempis⁵, ¹Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Spital Linth, Uznach, Switzerland, ³Private rheumatologic practice, Männedorf, Switzerland, ⁴Private rheumatologic practice, Triesen, Liechtenstein, ⁵Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland
The superiority of a treat to target strategy over conventional treatment with fixed csDMARD and corticosteroids: a multi-centre randomized controlled trial in RA patients with…
Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Brian C. Sauer¹, Chia-Chen Teng, MS¹, Neil A. Accortt², David H. Collier², Tzu-Chieh Lin² and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…
Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Gyanendra Pokharel¹, Rob Deardon¹, Cheryl Barnabe², Vivian P. Bykerk³, Susan J. Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Janet E. Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Glen Hazlewood¹², ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁶Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
Abstract Number: 2875 • 2018 ACR/ARHP Annual Meeting
Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
Jay Lin¹, Jeannie Choi², Jeffrey R. Curtis³, Melissa Lingohr-Smith¹ and Susan Boklage⁴, ¹Novosys Health, Green Brook, NJ, ²Sanofi, Bridgewater, NJ, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), the addition of a biologic DMARD…
Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks¹, Tracy Doyle², Jie Huang¹, Beatrice Pan², Elaine Fletcher², Ritu Gill³, Hiroto Hatabu², Mizuki Nishino⁴, David Murphy², Taysir Mahmoud², Christine K Iannaccone⁵, Michelle Frits², Bing Lu⁶, Ivan O. Rosas⁷, Paul Dellaripa², Michael E Weinblatt⁵, Elizabeth Karlson⁶ and Nancy A. Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Beth-Israel Deaconess Medical Center, Boston, MA, ⁴Dana-Farber Cancer Institute, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁷BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
Abstract Number: 2982 • 2018 ACR/ARHP Annual Meeting
Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Pomme Poppelaars¹, Lilian van Tuyl² and Maarten Boers^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, Epidemiology & Biostatistics | VU University Medical Center, Netherlands, Amsterdam, Netherlands
ACR abstractBackground/Purpose: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more…
Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J Mease¹, Neil Accortt², Mei Liu³, Sabrina Rebello³, Mahdi Gharaibeh² and David Collier², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Amgen Inc., Thousand Oaks, CA, ³Corrona, LLC, Southborough, MA
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
Abstract Number: 1703 • 2017 ACR/ARHP Annual Meeting
A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One Tnfα Inhibitor
Suzanne Kafaja¹, Donna Skerrett², Silviu Itescu³ and Daniel E. Furst⁴, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Mesoblast Inc., New York, NY, ³mesoblast Inc., New York, NY, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Allogeneic STRO-3 immunoselected mesenchymal precursor cells (MPCs) derived from bone marrow of healthy donors are a potent, homogeneous cell population which can be activated…
Abstract Number: 353 • 2017 ACR/ARHP Annual Meeting
Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey
Cheryl L. Koehn¹, Kelly Lendvoy¹, Yue Ma², Linda Li³, Alison Hoens⁴, Marion Souveton⁵ and John M. Esdaile⁴, ¹Arthritis Consumer Experts, Vancouver, BC, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Despite the global prevalence of rheumatoid arthritis (RA), there is no single model of care (MoC) and little is known about the RA patient…
Abstract Number: 1736 • 2017 ACR/ARHP Annual Meeting
Deep Immunophenotyping of T-Lymphocytes with a 37-Channel Mass Cytometry (CyTOF) Panel for the Identification of Pathological Cell Functions and the Prediction of Response to Biologic Drugs in Rheumatoid Arthritis
Ben Mulhearn^1,2,3, Darren Plant², Ann W. Morgan^4,5, Anthony G. Wilson⁶, John D Isaacs^7,8, Jane Worthington⁹, Soumya Raychaudhuri^9,10,11,12, Tracy Hussell¹, Anne Barton^13,14 and Sebastien Viatte², ¹Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Genetics and Genomics, , Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Medicine, Biology and Health, Manchester, United Kingdom, ³Kellgren Centre for Rheumatology, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, ⁷Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁸National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁰Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ¹²Partners Center for Personalized Genetic Medicine, Boston, MA, ¹³Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom, ¹⁴The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Pathogenic immune cell types and functions have not been identified yet in rheumatoid arthritis (RA). This is explained by the impact of disease heterogeneity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].